This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.

Inclusion Criteria:

• Participants who have received at least one dose of ADP adoptive cell therapy agent.
• Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
• Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• The investigator is responsible for review of medical history.
• Capable of giving signed informed consent.

Exclusion Criteria:

- None